CalciMedica director acquires 1.18M company shares

CalciMedica director Robert N. Wilson acquired 1,182,621 shares of Common Stock at $0.8033 per share.

Accepted by SEC EDGAR 06/29/2026 - 08:45 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CalciMedica director Robert N. Wilson acquired 1,182,621 shares of Common Stock at $0.8033 per share. After this transaction, he directly holds 1,604,650 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent board committee and closed on June 25, 2026.

Insider Trade Summary

Grant/Award: 1,182,621 shares

Grant/Award 1 txn

Insider WILSON ROBERT N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,182,621	$0.8033	$950K

Holdings After Transaction: Common Stock — 1,604,650 shares (Direct)

Footnotes (1)

1. F1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

Key Figures

Shares acquired: 1,182,621 shares Acquisition price: $0.8033 per share Total holdings after transaction: 1,604,650 shares +3 more

6 metrics

Shares acquired 1,182,621 shares Common Stock acquired on June 25, 2026

Acquisition price $0.8033 per share Price under Securities Purchase Agreement

Total holdings after transaction 1,604,650 shares Direct ownership following June 25, 2026 acquisition

Transaction code A (grant, award, or other acquisition) Non-derivative Form 4 transaction classification

Agreement date June 23, 2026 Date of Securities Purchase Agreement

Closing date June 25, 2026 Closing of share issuance under the agreement

Key Terms

Securities Purchase Agreement, independent committee, Common Stock, grant, award, or other acquisition

4 terms

Securities Purchase Agreement financial

"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

independent committee regulatory

"approved by an independent committee of the Issuer's Board of Directors"

An independent committee is a group of individuals within a company who are tasked with reviewing important decisions, such as mergers or acquisitions, without influence from the company's management or major shareholders. Their role is to provide impartial judgment, helping ensure that decisions are made fairly and in the best interest of all stakeholders. For investors, this adds a layer of objectivity and transparency to significant corporate actions.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CalciMedica (CALC) report for Robert N. Wilson?

CalciMedica reported that director Robert N. Wilson acquired 1,182,621 shares of Common Stock. The acquisition was recorded as a grant or award-type transaction at $0.8033 per share, significantly increasing his directly held stake in the company.

At what price were the new CalciMedica (CALC) shares acquired by the director?

The 1,182,621 CalciMedica Common Stock shares were acquired at $0.8033 per share. This price reflects the per-share consideration under the Securities Purchase Agreement governing the issuance from the company to director Robert N. Wilson.

How many CalciMedica (CALC) shares does Robert N. Wilson hold after this Form 4 transaction?

Following the reported acquisition, Robert N. Wilson directly holds 1,604,650 shares of CalciMedica Common Stock. This total includes the 1,182,621 shares obtained in the June 25, 2026 closing under the Securities Purchase Agreement with the issuer.

What agreement governed the CalciMedica (CALC) share issuance to Robert N. Wilson?

The share issuance to Robert N. Wilson was governed by a Securities Purchase Agreement dated June 23, 2026. The transaction closed on June 25, 2026 and involved the company issuing Common Stock directly to the director under approved terms.

Who approved the CalciMedica (CALC) Securities Purchase Agreement for this insider share acquisition?

An independent committee of CalciMedica’s Board of Directors approved the Securities Purchase Agreement. This committee also approved the issuance of the Common Stock to director Robert N. Wilson under that agreement, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON ROBERT N

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		A(1)		1,182,621	A	$0.8033	1,604,650	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

	/s/ John Dunn, Esq., Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)